Suven Life Sciences Limited (SUVEN.BO)
- Previous Close
113.19 - Open
113.61 - Bid 111.45 x --
- Ask 111.77 x --
- Day's Range
110.51 - 114.25 - 52 Week Range
55.01 - 128.79 - Volume
17,532 - Avg. Volume
34,280 - Market Cap (intraday)
24.309B - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-4.77 - Earnings Date May 7, 2024 - May 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Feb 14, 2019
- 1y Target Est
292.00
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
www.suven.com132
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: SUVEN.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUVEN.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUVEN.BO
Valuation Measures
Market Cap
24.31B
Enterprise Value
22.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
203.34
Price/Book (mrq)
7.18
Enterprise Value/Revenue
187.46
Enterprise Value/EBITDA
-22.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
119.74M
Net Income Avi to Common (ttm)
-1.06B
Diluted EPS (ttm)
-4.77
Balance Sheet and Cash Flow
Total Cash (mrq)
1.98B
Total Debt/Equity (mrq)
0.35%
Levered Free Cash Flow (ttm)
--
Research Analysis: SUVEN.BO
Company Insights: SUVEN.BO
SUVEN.BO does not have Company Insights